Literature DB >> 31833168

Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.

Martin Möckel1, Rudolf A de Boer2, Anna Christine Slagman1, Stephan von Haehling3, Morten Schou4, Jörn Ole Vollert5, Jan C Wiemer5, Stefan Ebmeyer5, F Javier Martín-Sánchez6, Alan S Maisel7, Evangelos Giannitsis8.   

Abstract

AIM: To determine whether initiation of antibiotic therapy (ABX) by procalcitonin (PCT) within 8 h of admission in patients presenting to the emergency department with symptoms and signs of acute heart failure (AHF) and elevated natriuretic peptides would improve clinical outcomes. METHODS AND
RESULTS: The study was a randomized multicentre clinical trial conducted at 16 sites in Europe. Patients were randomized to either a PCT-guided strategy or standard care. Patients with PCT-guided strategy (n = 370) had ABX initiated if PCT was > 0.2 μg/L. Patients with standard care (n = 372) had AHF care in accordance with published guidelines without PCT. The primary endpoint was 90-day all-cause mortality. Pre-specified secondary endpoints included 30-day all-cause mortality and readmission and rate of pneumonia. The Data Safety and Review Committee recommended stopping the study for futility when 762 of the planned 792 patients had been enrolled. A total of 742 patients could be analysed. Patients were elderly (median age: 77 years), 38% were women, and had typical signs and symptoms of AHF. All-cause mortality at 90 days was 10.3% in the PCT-guided group vs. 8.2% in standard care (P = 0.316). Thirty-day readmission was significantly higher in the PCT-guided group vs. standard care but the difference vanished until day 90. The rate of pneumonia was overall low (7.5%) and not different between groups.
CONCLUSIONS: In patients with AHF, a strategy of PCT-guided initiation of ABX was not more effective than a standard care strategy in improving clinical outcomes.
© 2019 The Authors.European Journal of Heart Failure © 2019 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; Antibiotic therapy; Mortality; Natriuretic peptides; Procalcitonin

Mesh:

Substances:

Year:  2019        PMID: 31833168     DOI: 10.1002/ejhf.1667

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  5 in total

Review 1.  Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment.

Authors:  Nicholas Wettersten
Journal:  Int J Heart Fail       Date:  2021-02-15

Review 2.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

3.  Acute Bacterial Infections and Longitudinal Risk of Readmissions and Mortality in Patients Hospitalized with Heart Failure.

Authors:  Tien M H Ng; Esther E Oh; Yuna H Bae-Shaaw; Emi Minejima; Geoffrey Joyce
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

4.  Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection.

Authors:  Fabrice F Darche; Moritz Biener; Matthias Müller-Hennessen; Rasmus Rivinius; Kiril M Stoyanov; Barbara R Milles; Hugo A Katus; Norbert Frey; Evangelos Giannitsis
Journal:  Life (Basel)       Date:  2021-12-18

Review 5.  Antimicrobial Stewardship Using Biomarkers: Accumulating Evidence for the Critically Ill.

Authors:  Evdoxia Kyriazopoulou; Evangelos J Giamarellos-Bourboulis
Journal:  Antibiotics (Basel)       Date:  2022-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.